pifithrin has been researched along with Dysmyelopoietic Syndromes in 2 studies
pifithrin: a tetrahydrobenzothiazol; inhibitor of P53 that protects mice from the side effects of cancer therapy; structure in first source
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dutt, S | 1 |
| Narla, A | 1 |
| Lin, K | 1 |
| Mullally, A | 1 |
| Abayasekara, N | 1 |
| Megerdichian, C | 1 |
| Wilson, FH | 1 |
| Currie, T | 1 |
| Khanna-Gupta, A | 1 |
| Berliner, N | 1 |
| Kutok, JL | 1 |
| Ebert, BL | 1 |
| Xu, H | 1 |
| Menendez, S | 1 |
| Schlegelberger, B | 1 |
| Bae, N | 1 |
| Aplan, PD | 1 |
| Göhring, G | 1 |
| Deblasio, TR | 1 |
| Nimer, SD | 1 |
2 other studies available for pifithrin and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells.
Topics: Anemia, Diamond-Blackfan; Anemia, Macrocytic; Animals; Benzothiazoles; Cell Cycle; Cell Lineage; Cel | 2011 |
Loss of p53 accelerates the complications of myelodysplastic syndrome in a NUP98-HOXD13-driven mouse model.
Topics: Animals; Benzothiazoles; Cell Transformation, Neoplastic; Disease Models, Animal; Female; Flow Cytom | 2012 |